Appropriate Treatment Approaches in Patients Through Every Stage of Hodgkin Lymphoma

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 26, 2019
Expiration Date: June 26, 2020

Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will address several practice-related issues regarding the management and treatment of patients with Hodgkin lymphoma (HL). Nurses who provide care to patients with HL may encounter clinical challenges regarding appropriate treatments and the adverse events associated with them. In this activity, you will hear from four experts focusing on topics including, but not limited to: emerging treatment regimens for newly diagnosed HL, recent clinical trials that are making an impact on the frontline management of advanced-stage cHL, current salvage treatment options for relapsed/refractory cHL, and CD30-directed therapy.

Target Audience

This activity is designed for nurses in the community setting who provide care to patients with Hodgkin lymphoma.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Explain the latest clinical data regarding the efficacy and safety of emerging agents for newly diagnosed patients with HL
  • Describe strategies to individualize HL treatment and account for patient preferences based on clinical trial data
  • Describe the role of immunotherapy in relapsed/refractory HL
  • Outline current and emerging strategies for the treatment of advanced HL

Agenda

Individualized Treatment Approaches in Patients with Newly Diagnosed Hodgkin Lymphoma – Alison J. Moskowitz, MD

Advanced-stage cHL: Rethinking Our Options in Frontline Therapy – Jonathon B. Cohen, MD, MS

The Treatment of R/R cHL in the Era of Checkpoint Inhibitors – Catherine Diefenbach, MD

Treating Advanced HL in 2019 – Sarah Rutherford, MD

Instructions for Participation and Credit

This activity is eligible for credit through June 26, 2020. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CNE may be printed immediately after successfully completing the post-test and activity evaluation.

Faculty Biographies

Jonathon B. Cohen, MD, MS
Assistant Professor
Hematology and Medical Oncology
Emory University School of Medicine
Atlanta, Georgia

Dr. Jonathon Cohen received his medical degree at the University of Florida College of Medicine. He completed a residency in internal medicine and fellowship in hematology and medical oncology at The Ohio State University in Columbus, Ohio. During his fellowship, he also completed a master’s degree in medical science, gathering additional training in the conduct of clinical and translational research. Dr. Cohen is an Assistant Professor in Hematology and Medical Oncology at the Emory University School of Medicine in Atlanta.

Dr. Cohen’s clinical focus is on the treatment of Hodgkin and non-Hodgkin lymphoma, where he manages both newly diagnosed patients as well as those requiring stem cell transplantation and treatment for relapsed disease. His research focus includes the clinical investigation of lymphoma, where he aims to identify prognostic markers and designs clinical trials with novel agents for patients with relapsed disease. Dr. Cohen has been recognized as a promising young investigator as evidenced by his selection to participate in the ASCO/AACR Methods in Clinical Cancer Research workshop and the American Society of Hematology Clinical Research Training Institute.

Catherine Diefenbach, MD
Assistant Professor of Medicine
Clinical Director of Lymphoma
Department of Hematology/Oncology
NYU Langone Medical Center
New York, New York

Dr. Catherine Diefenbach received her medical degree from the University of Pennsylvania School of Medicine. She completed her internship and residency at the Johns Hopkins Hospital and her oncology fellowship at Memorial Sloan Kettering Cancer Center, where she spent an additional year focusing on translational immunology. Dr. Diefenbach is an Assistant Professor of Medicine, and the Clinical Director of Lymphoma in the Department of Hematology/Oncology at the NYU Langone Medical Center and a member of its Laura and Isaac Perlmutter Cancer Center. Additionally, she directs the lymphoma clinical research within the Hematology Division at the Perlmutter Cancer Center.

Dr. Diefenbach serves on the ECOG Lymphoma Committee, the Grants Committee of the ASCO Conquer the Cancer Foundation, the ASH Communications Committee, and is on the editorial board of Clinical Cancer Research. She is a translational physician-scientist specializing in the care of patients with Hodgkin and non-Hodgkin lymphoma, whose research is supported by the American Cancer Society, the National Cancer Institute (NCI), and the Doris Duke Foundation, and previously by the Lymphoma Research Foundation. Dr. Diefenbach’s scientific research focuses on the relationship between lymphoma and immunity; on developing novel and immune based treatment strategies for patients with relapsed lymphoma; and on biomarker discovery. 

Alison J. Moskowitz, MD
Clinical Director, Lymphoma Inpatient Unit
Assistant Attending, Lymphoma Service
Memorial Sloan Kettering Cancer Center
New York, New York

Dr. Alison Moskowitz received her medical degree from Albert Einstein College of Medicine in the Bronx. She completed her internal medicine residency and internship at Columbia University Medical Center, followed by hematology/medical oncology fellowships at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York City. Dr. Moskowitz is Clinical Director of the Lymphoma Inpatient Unit, and Assistant Attending, Lymphoma Service, at Memorial Sloan Kettering Cancer Center in New York.

Dr. Moskowitz is board certified in internal medicine, medical oncology, and hematology. She holds professional membership in the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH). Dr. Moskowitz has lectured and authored/co-authored peer-reviewed articles on autologous stem cell transplantation, relapsed/refractory Hodgkin lymphoma, and T-cell lymphoma. Her primary research focus is on evaluating novel treatments for Hodgkin lymphoma.

Sarah Rutherford, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Weill Cornell Medicine
New York, New York

Dr. Sarah Rutherford received her medical degree from the University of Virginia School of Medicine. She completed her internship and residency in internal medicine at Thomas Jefferson University Hospital in Philadelphia and her fellowship in hematology/oncology at New York-Presbyterian Hospital/Weill Cornell Medical College. She is an Assistant Professor of Medicine in the Division of Hematology/Oncology at Weill Cornell Medicine, New York City.

Dr. Rutherford has clinical expertise in lymphoma. Her research focuses on novel therapeutic strategies in B-cell lymphomas. She has received honors from Weill Cornell Medical College and the American Society of Hematology, and support from the New York State Empire Clinical Research Investigator Program, the Lymphoma Research Foundation, and the National Institutes of Health Clinical Loan Repayment Program. She has experience in caring for patients with a variety of lymphomas and hematologic disorders including Hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma.

Accreditation

MediCom CNE CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 19-015-104

Disclosures

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jonathon Cohen has received honoraria as a consultant from Celgene Corporation, Extera, Genentech, Inc., and Pharmacyclics, Inc. He has received grant support related to research activities from AbbVie Inc., Bristol-Myers Squibb Company, and Seattle Genetics, Inc.

Dr. Catherine Diefenbach has received honoraria as a consultant from Bayer AG, Bristol-Myers Squibb Company, Genentech, Inc., Merck & Co., Inc., and Seattle Genetics, Inc. She has received grant support related to research activities from Bristol-Myers Squibb, Genentech, LAM Therapeutics, Inc., MEI Pharma Inc., Merck & Co., Millennium Pharmaceuticals, Inc., and Seattle Genetics. She owns significant holdings in Gilead.

Dr. Alison Moskowitz has received honoraria as a consultant from Cell Medica, Kyowa Hakko Kirin Co., Ltd., and Seattle Genetics, Inc.

Dr. Sarah Rutherford has received honoraria as a consultant from AstraZeneca, Celgene Corporation, Heron Therapeutics, Inc., Juno Therapeutics, Karyopharm Therapeutics, and Seattle Genetics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at lisa@medicaled.com.

This activity is supported by educational grants from Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics, Inc.

©2019 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to recognize and thank Bristol-Myers Squibb, Merck & Co., Inc., and Seattle Genetics for their educational support. To better serve the needs of our audience, ManagingHodgkinLymphoma.com is now ManagingLymphoma.com

©2019 MediCom Worldwide, Inc. All rights reserved